Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study
Akiko Morinaga, Takehisa Hirayama, Makiko Nagai, Osamu Kano et al.
Citations
8 citations
Journal
BMJ Open
Topics
Amyotrophic Lateral Sclerosis Research
Field-Weighted Citation Impact (FWCI)
2.95
article
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study
Hiroshima University (JP), Toho University (JP), Aichi Medical University (JP), Pfizer (United States) (US), Akita University (JP), Kyoto University (JP), National Institutes for Quantum Science and Technology (JP), Pfizer (Japan) (JP), Kyoto University Hospital (JP), Tottori University (JP), Kitasato University (JP), Nara Medical University (JP), Tokushima University (JP)
Funders
Pfizer, Japan Agency for Medical Research and Development